Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

NCT02365415 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.

NCT NCT02365415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02365415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
Lead sponsor
Boston Children's Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2015
Completion date
April 30, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

in-stent stenosis, peripheral pulmonary stenosis